Advertisement

One Response

  1. Jim Paige
    Jim Paige June 8, 2008 at 7:12 pm | | Reply

    According to a Reuter’s article referenced by Yahoo News, “Patients in the intensive arm of Advance were treated primarily with moderate-release gliclazide, a drug in an older class known as sulfonylureas.

    Dluhy and McMahon noted that few patients in Advance got drugs in a new class called thiazolidinediones or glitazones. But rosiglitazone — GlaxoSmithKline Plc’s Avandia — was given to 90 percent of the intensive therapy group in Accord.

    Hello? 90% of patients in the intensive therapy group in the Accord study were given AVANDIA – this is the Avandia that pretty much is proven to cause heart failure, yes??!!!

    And the egg heads are wondering why there were more deaths in the intensive AVANDIA Accord group?

    Hello, McFly, knock-on-the-head, knock-on-the-head, knock-on-the-head!

Leave a Reply